Background: α particle emitting bismuth (²¹²Bi) as decay product of ²¹²Pb-labeled pharmaceuticals has been effective in targeted α particle therapy (TAT). Estimating the contribution of ²¹²Bi released from its chelator to the absorbed doses in nontarget tissues is challenging in TAT. Physiologically based pharmacokinetic (PBPK) modeling can help overcome this limitation. Therefore, a whole-body ²¹²Bi–PBPK model was developed to describe the pharmacokinetics (PKs) of ²¹²Bi in rats.

中文翻译：

---

大鼠 α 粒子释放铋的全身生理药代动力学模型

背景： α粒子发射铋（ ²¹² Bi）作为²¹² Pb 标记药物的衰变产物在靶向 α 粒子治疗（TAT）中是有效的。估计从螯合剂释放的²¹² Bi 对非靶组织吸收剂量的贡献在 TAT 中具有挑战性。基于生理的药代动力学 (PBPK) 建模可以帮助克服这一限制。因此，开发了一个全身²¹² Bi-PBPK 模型来描述²¹² Bi 在大鼠中的药代动力学 (PK)。